Overactive bladder syndrome (OBS) causes a frequent, uncontrolled urge to urinate, which can interfere with a person’s daily activities and affect their mental health. A new hydrogel-based device has been developed that can continuously monitor overactive bladders and has the potential to improve the treatment of the condition. Read more.
Source: New Atlas, March 13, 2023
Zida has recently launched “The Zida Control Sock” to help individuals suffering from overactive bladder and incontinence reduce their symptoms. The Zida Control Sock is an FDA-cleared neuromodulation device that uses transcutaneous tibial nerve stimulation to treat overactive bladder and incontinence. Read more.
Source: Newsfile Corp., January 11, 2023
Combining Myrbetriq (mirabegron) with modifications like pelvic floor exercises failed to ease overactive bladder symptoms in people with Parkinson’s disease in a pilot clinical trial, the study’s main goal. But the treatment, approved for overactive bladder, when used with such behavioral modifications did increase the amount of urine patients were able to expel with each urination, relative to patients using only pelvic floor exercise. But this benefit was temporary. Read more.
Source: Parkinson’s News Today, December 7, 2022
Unmet socioeconomic needs had a significant association with overactive bladder (OAB), adding to evidence of a complex interaction between social determinants of health and OAB, researchers said. Stressors such as housing and food insecurity and concerns about personal health as much as tripled the odds of reported OAB symptoms. The stressors remained significant predictors for OAB after adjustment for multiple demographic and medical factors. Unmet socioeconomic needs had a stronger association with OAB with urge urinary incontinence (UUI, “wet” OAB), reported Elisabeth M. Sebesta, MD, of Vanderbilt University Medical Center in Nashville, Tennessee, and co-authors in the Journal of Urology. Read more.
Source: MedPage Today, December 1, 2022
Neuspera® Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced the first patient successfully implanted with the Nuvella™ system in its pivotal clinical trial (SANS-UUI). The procedure was performed by Dr. Jodi Michaels of Minnesota Urology, St. Paul, MN. The study will evaluate the safety and efficacy of the Nuvella system, designed to treat overactive bladder (OAB) with sacral neuromodulation (SNM) in patients with urinary urgency incontinence (UUI) symptoms. Read more.
Source: PRNewsire, October 10, 2022
The impact and management of urinary incontinence (UI) related to overactive bladder is a substantial burden to long-term care (LTC) residents and staff, according to a study published online July 1 in the Journal of Gerontological Nursing. Richard G. Stefanacci, D.O., from Thomas Jefferson University in Philadelphia, and colleagues assessed the impact of UI on residents, staff, care processes, and quality measures in LTC settings. The analysis included responses from directors of nursing who had worked for at least one year in a ≥100-bed facility. Read more.
Source: Health Day News, July 25, 2022
Patients with COVID-19 infection are at increased risk of developing new or worsening symptoms of overactive bladder (OAB), according to data presented at the American Urological Association’s annual meeting in 2022 in New Orleans, Louisiana. Ly Hoang Roberts, MD, of Oakland University, Royal Oak, Michigan, and colleagues noted that they were the first American group to identify de novo genitourinary symptoms, such as frequency, urgency, nocturia, and pain / pressure in people with previous COVID 19 infection. They called this condition COVID-19 associated cystitis (CAC). Read more.
Source: Community 99, May 15, 2022
After receiving an FDA approval last month in bladder and bowel incontinence for its neuromodulation device implanted in the lower back, Medtronic isn’t resting on its laurels. It has begun a clinical trial of a similar system placed near the ankle, which the company described as a more convenient option that may make the therapy available to more people. The medtech giant announced that its first patients have received implants in the pivotal study, with neurostimulators that tap into the posterior tibial nerve running up the back of the leg, to transmit electrical pulses that aim to help regulate an overactive bladder. Read more.
Source: Fierce Biotech, March 25, 2022
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has approved its newly developed, long-lived, recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS). Read more.
Source: Business Wire, March 7, 2022
Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced positive topline results from its Phase 2a, double-blind, placebo-controlled exploratory study of URO-902, an investigational, novel, locally injected gene therapy product (plasmid human cDNA encoding maxi-K channel), in patients with overactive bladder (OAB), who were not well managed by oral therapies. Read more.
Source: Pharmiweb.com, March 7, 2022